Investor disappointment as vaccines again come up short, despite the Q3 beat
30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."
Pages
65
Language
English
Published on
30/10/24
You may also be interested by these reports :
30/10/24
On the back of the strong performance from Biosimilars, Sandoz again upgraded its full-year outlook. Given that the markets had doubted the firm’s ...
30/10/24
Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for ...
30/10/24
We have raised our 2024 estimates on the back of the management’s vague comments on the positive development for profitability in the Q3. We expect ...
29/10/24
Novartis exceeded expectations with Q3 profitability, and the management upgraded its full-year guidance for the third time this year. Nonetheless, ...